UNC7467 is a potent IP6K inhibitor with IC50 values of 4.9 nM for IP6K2, 8.9 nM for IP6K1, and 1320 nM for IP6K6. It effectively reduces inositol pyrophosphate levels without significantly affecting other inositol phosphates and is applicable for obesity research [1].

UNC7467 (2.5 μM; 3 hours; HCT116 cells) reduces inositol pyrophosphate levels, decreasing 5-InsP7 by 81% and 5-InsP8 by 63% [1].

UNC7467, administered at a dosage of 5 mg/kg through intraperitoneal injection daily for 4 weeks, significantly ameliorated diet-induced obesity, insulin resistance, and hepatic steatosis in mice with diet-induced obesity (DIO). This compound also demonstrated considerable pharmacokinetic benefits in DIO mice, presenting a low clearance rate of 13.7 (mL/min)/kg and yielding substantial area under the curve (AUC) values of 6054 h ng/mL for intravenous (i.v.) and 2527 h ng/mL for intraperitoneal (i.p.) routes at a 5 mg/kg dose. Furthermore, it improved glycemic profiles, mitigated hepatic steatosis, and curbed weight gain without affecting the mice's food intake. These findings underscore UNC7467's potential as an efficacious agent for treating diet-induced obesity and related metabolic disorders.

DMSO: 3.16 mg/mL (10.02 mM), Sonication is recommended.